These clinical investigations have revealed that high levels of serum IGF-1 and/or decreased concentrations of IGF-1 binding proteins are linked to an augmented risk for several malignancies [16], including breast cancer [19, 50, 51], prostate [18, 52], lung [53], and colorectal cancer [54-56]. The gene discussed is IGF1; the disease is breast cancer.